Beta Drugs (NSE:BETA) Debt-to-Equity: N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BETA Beta Drugs Ltd NSE:BETA
91 GF Score
Price ₹2,327.70
GF Value ₹2,699.21
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Beta Drugs Debt-to-Equity?

Beta Drugs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Beta Drugs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Beta Drugs's Total Stockholders Equity for the quarter that ended in Jun. 2026 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Beta Drugs's Debt-to-Equity or its related term are showing as below:

NSE:BETA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09   Med: 0.24   Max: 1.35
Current: 0.6

During the past 13 years, the highest Debt-to-Equity Ratio of Beta Drugs was 1.35. The lowest was 0.09. And the median was 0.24.

NSE:BETA's Debt-to-Equity is ranked worse than
74.85% of 811 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs NSE:BETA: 0.60

Beta Drugs  (NSE:BETA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Beta Drugs Debt-to-Equity Related Terms

Beta Drugs Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Beta Drugs's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs Debt-to-Equity Chart

Beta Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.17 0.09 0.70 0.60

Beta Drugs Quarterly Data
Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.66 N/A 0.60 N/A

NSE:BETA vs ZTS: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beta Drugs Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Beta Drugs's Debt-to-Equity falls into.


NSE:BETA
91GF Score
Beta Drugs Ltd NSE:BETA
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Drugs Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Beta Drugs's Debt to Equity Ratio for the fiscal year that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(144.821 + 1333.247) / 2447.705
=0.60

Beta Drugs's Debt to Equity Ratio for the quarter that ended in Jun. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be undervalued. The current stock price of ₹2,327.70 is trading 13.8% below its estimated GF Value™ of ₹2,699.21. GuruFocus considers Beta Drugs to be Modestly Undervalued.

Key valuation signals for NSE:BETA:

  • Debt-to-Equity: N/A
  • GF Value™: ₹2,699.21 vs. price of ₹2,327.70 (13.8% below fair value)
  • GF Score™: 91/100 with 6 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
91GF Score

Get the complete analysis for NSE:BETA

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,327.70
Price
₹2,699.21
GF Value